Doxorubicin Selection Leads to ABCG2 Overexpression in Cancer Cells
Author Information
Author(s): Calcagno A M, Fostel J M, To K K W, Salcido C D, Martin S E, Chewning K J, Wu C-P, Varticovski L, Bates S E, Caplen N J, Ambudkar S V
Primary Institution: National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
Hypothesis
Single-step selection with low doses of doxorubicin induces multidrug resistance mediated by ABCG2.
Conclusion
The study found that low-dose doxorubicin selection leads to the overexpression of ABCG2, contributing to drug resistance in cancer cells.
Supporting Evidence
- ABCG2 was overexpressed in multiple cancer cell lines after low-dose doxorubicin selection.
- RNA interference confirmed that ABCG2 confers drug resistance.
- Histone hyperacetylation was linked to the upregulation of ABCG2.
- ABCC4 and ABCC2 were also overexpressed but did not confer resistance.
- Single-step selection mimicked in vivo drug concentrations more closely than traditional methods.
Takeaway
When cancer cells are exposed to a little bit of a drug called doxorubicin, they can learn to fight it off better by making more of a special protein called ABCG2.
Methodology
The study involved selecting breast, ovarian, and colon cancer cells with low doses of doxorubicin and analyzing gene expression and drug resistance.
Limitations
The study does not fully rule out the presence of pre-existing resistant cells in the parental population.
Participant Demographics
The study involved breast, ovarian, and colon cancer cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website